Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

Eligibility criteria:
Inclusion criteria:

        A. Males and females of age 18-55. B. A diagnosis of epigastric pain/discomfort (located in
        the upper abdomen) rated by the patient as moderate to severe in intensity (on a four-point
        categorical scale), which has been present at least 3 times per week for 12 weeks,
        unrelated to exercise.

        C. Patients may have other symptoms of NUD including heartburn, regurgitation, bloating
        (abdominal distension), early satiety (feeling of fullness), belching (burping), or nausea;
        however, the dominant symptom must be epigastric pain/discomfort.

        D. Capable of and willing to give informed consent and comply with all study requirements.

        Exclusion criteria:

        A. H. pylori positive serology. B. Regular use of NSAIDs or more than 100 mg of aspirin. C.
        Patients requiring chronic treatment with any medication inducing GI symptoms (e.g.,
        certain antibiotics, codeine, etc.).

        D. History or presence of endoscopic/radiological evidence of esophagitis. E. History or
        presence of chronic gastric or duodenal ulcer. F. History or presence of duodenal erosions.
        G. History or previous upper GI surgery. H. Presence of concomitant symptoms of irritable
        bowel syndrome (IBS) as assessed by three or more of the Manning or Rome criteria.

        I. History or presence of other known organic disease that might explain the dyspepsia
        symptoms (e.g., symptomatic gallstones).

        J. Pregnancy or lactation. K. Inadequate contraception. L. Regular consumption of greater
        than 2 fluid ounces of beverage alcohol (corresponding to 2 cocktails or 40 fluid ounces of
        beer or 16 fluid ounces of wine) per day.

        M. History of substance abuse. N. Unwillingness or expected inability to tolerate absence
        of antisecretory medications (antacids, H2 receptor antagonists or Proton pump inhibitors
        (PPIs) or other GI pharmacotherapy for a period of time of study protocol (16 weeks
        maximum).
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 55 Years

Eligibility (NLI label): Entailment